0001104659-21-128639.txt : 20211021
0001104659-21-128639.hdr.sgml : 20211021
20211021204952
ACCESSION NUMBER: 0001104659-21-128639
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211021
FILED AS OF DATE: 20211021
DATE AS OF CHANGE: 20211021
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAY CITY CAPITAL LLC
CENTRAL INDEX KEY: 0001288452
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40925
FILM NUMBER: 211338453
BUSINESS ADDRESS:
STREET 1: 750 BATTERY STREET STE 400
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
BUSINESS PHONE: 415.676.3830
MAIL ADDRESS:
STREET 1: 750 BATTERY STREET STE 400
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
FORMER NAME:
FORMER CONFORMED NAME: BAY CITY CAPITAL FUND LLC
DATE OF NAME CHANGE: 20040423
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xilio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840233
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851623397
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-833-1027
MAIL ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
3
1
tm2130646-12_3seq1.xml
OWNERSHIP DOCUMENT
X0206
3
2021-10-21
0
0001840233
Xilio Therapeutics, Inc.
XLO
0001288452
BAY CITY CAPITAL LLC
1000 4TH STREET, SUITE 500
SAN RAFAEL
CA
94901
0
0
1
0
Series B Preferred Stock
Common Stock
665696
I
See footnotes
Series C Preferred Stock
Common Stock
151294
I
See footnotes
The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.
Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
/s/ Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership, By: Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company, its General Partner, By: Fred Craves, Director
2021-10-21
/s/ Bay City Capital LLC, a Delaware limited liability company, By: Fred Craves, Managing Director
2021-10-21